AlphaStocks

AZN vs BMY

ASTRAZENECA PLC vs BRISTOL MYERS SQUIBB CO — Side-by-Side Stock Comparison

AZN

ASTRAZENECA PLC

8.4

Strong Buy

$184.80

BMY

BRISTOL MYERS SQUIBB CO

7.0

Consider Buy

$56.55

AZN vs BMY: Which is the Better Investment?

ASTRAZENECA PLC (AZN) scores 8.4/10 while BRISTOL MYERS SQUIBB CO (BMY) scores 7.0/10 on AlphaStocks' composite model. ASTRAZENECA PLC has the higher composite rating of Strong Buy. On a P/E basis, BRISTOL MYERS SQUIBB CO trades at 16.4x, making it the more attractively priced of the two. BRISTOL MYERS SQUIBB CO offers more upside to its estimated fair value.

This comparison is algorithmically generated and is not financial advice.

MetricAZNBMY
Scores & Fundamentals
Composite Score8.4/107.0/10
RatingStrong BuyConsider Buy
Price$184.80$56.55
P/E Ratio28.216.4
ROE21.9%38.1%
Market Cap$289B$116B
Fair Value$192.63$88.73
Dividend Yield1.7%4.1%
Sector Rank#2 of 1126#67 of 1126
Model Verdicts
PiotroskiStrongStrong
BuffettStrongAttractive
GrahamCautionCaution
LynchNeutralNeutral
GreenblattNeutralAttractive
View full AZNanalysis →View full BMYanalysis →
Compare any two stocks →

AZN vs BMY: Which Stock Scores Higher?

ASTRAZENECA PLC (AZN) and BRISTOL MYERS SQUIBB CO (BMY) are among the most compared stocks in the Health Care sector. AZN currently leads with a composite score of 8.4/10 (Strong Buy) compared to BMY's 7.0/10 (Consider Buy).

The AlphaStocks composite score evaluates each stock across four dimensions: Quality (business strength measured by Piotroski F-Score and Buffett quality criteria), Value (discount to intrinsic worth using Graham, Lynch, and Greenblatt models), Momentum (6-month price trend), and Timing (a confirmation signal that requires both value and momentum to align). A higher composite score indicates stronger overall fundamentals combined with favorable market conditions.

This comparison uses the same scoring framework for both companies, ensuring an apples-to-apples evaluation. Scores are recalculated daily after market close using data from SEC filings and market prices. Read the full methodology to understand how each model contributes to the composite score.

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer